Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | HPGD | P15428 | 6/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | GRM5 | P41594 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | PHGDH | O43175 | 1/20 | 0.55 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.51 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20687922 | 0.85 | GRM5 (0.67) | SMN1; SMN2ALDH1A1HPGDKDM4EPOLB | |
| SCHEMBL5909240 | 0.85 | GRM5 (0.71) | ALDH1A1HPGDKDM4EPOLBALOX15 | |
| SCHEMBL5909310 | 0.84 | GRM5 (0.73) | ALDH1A1HPGDKDM4EPOLBALOX15 | |
| SCHEMBL26944349 | 0.83 | GRM5 (0.54) | SMN1; SMN2ALDH1A1HPGDRAB9AGRM5 | |
| SCHEMBL5908983 | 0.83 | GRM5 (0.58) | HPGDKDM4EPOLBALOX15RAB9A | |
| SCHEMBL2235373 | 0.83 | SMN1; SMN2 (0.72) | SMN1; SMN2ALDH1A1HPGDKDM4EPOLB | |
| SCHEMBL13210615 | 0.83 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1HPGDKDM4EPOLB | |
| SCHEMBL5909219 | 0.81 | POLB (0.60) | SMN1; SMN2ALDH1A1HPGDPOLBGRM5 | |
| SCHEMBL20255520 | 0.81 | SMN1; SMN2 (0.70) | SMN1; SMN2ALDH1A1HPGDKDM4EPOLB | |
| SCHEMBL11622646 | 0.81 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1HPGDKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022236253-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022236256-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| EP-4050012-A1 | PYRIDONE BORONATES FOR THE PREPARATION OF INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2022-08-31 | — | — | EP | disclosed |
| EP-4019508-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2022-06-29 | — | — | EP | disclosed |
| EP-3532473-B1 | HETEROBICYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3521288-B1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | HOFFMANN LA ROCHE (CH) | 2021-09-08 | — | — | EP | disclosed |
| EP-3426648-B1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | CTXT PTY LTD (AU) | 2021-05-12 | — | — | EP | disclosed |
| US-10781215-B2 | Heterobicyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-09-22 | — | — | US | disclosed |
| US-20190322672-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2019-10-24 | — | — | US | disclosed |
| EP-3521288-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2019-08-07 | — | — | EP | disclosed |
| EP-2206707-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | BLAKE TANISHA D | 2009-11-12 | — | — | US | disclosed |
| US-7582643-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090105209-A1 | BTK protein kinase inhibitors | ROCHE PALO ALTO LLC | 2009-04-23 | — | — | US | disclosed |
| US-20090005355-A1 | Piperidine Compound and Process for Preparing the Same | TANABE SEIYAKU CO., LTD. (JP) | 2009-01-01 | — | — | US | disclosed |
| US-20090005355-A1 | Piperidine Compound and Process for Preparing the Same | TANABE SEIYAKU CO., LTD. (JP) | 2009-01-01 | — | — | US | disclosed |
| WO-2008104869-A1 | NICOTINAMIDE DERIVATIVES AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | BLAKE TANISHA D | 2008-08-28 | — | — | US | disclosed |
| WO-2008075172-A2 | NICOTINAMIDE DERIVATIVES AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10781215-B2 | Heterobicyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | TYK2, IL2, IL23R | SMN1; SMN2 3901/4885ALDH1A1 4722/4885HPGD 3328/4885 |
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | CYP11B2, CYP11B1, LTC4S | SMN1; SMN2 1483/4885ALDH1A1 134/4885HPGD 57/4885 |
| US-20090105209-A1 | BTK protein kinase inhibitors | BTK, SYK, LYN | SMN1; SMN2 4495/4885ALDH1A1 3990/4885HPGD 3768/4885 |
| US-20190322672-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | TYK2, IL2, IFNG | SMN1; SMN2 4246/4885ALDH1A1 4783/4885HPGD 3066/4885 |
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | SMN1; SMN2 1371/4885ALDH1A1 148/4885HPGD 18/4885 |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | CYP11B2, CYP11B1, LTC4S | SMN1; SMN2 1483/4885ALDH1A1 134/4885HPGD 57/4885 |
| US-20090005355-A1 | Piperidine Compound and Process for Preparing the Same | AVPR1B, HRH4, PRLHR | SMN1; SMN2 4150/4885ALDH1A1 2868/4885HPGD 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.